Literature DB >> 2299354

Treatment with oxiracetam or choline restores cholinergic biochemical and pharmacological activities in striata of decorticated rats.

S Consolo1, P Salmoiraghi, D Amoroso, K Kolasa.   

Abstract

Interruption of the corticostriatal pathway by undercutting the frontal cortex resulted after 2 weeks in a 40% reduction of basal acetylcholine (ACh) release in vivo, and in inhibition of the striatal sodium-dependent high-affinity uptake of choline (SDHACU) to the same extent. The lesion, too, completely prevented the rise (about 35%) in striatal ACh content induced by oxotremorine and apomorphine acting at muscarine and dopamine receptors, respectively. Acute intraperitoneal injections of 100 mg/kg of either oxiracetam or choline chloride resulted in time-dependent recovery of ACh output from the striata of decorticated rats to control levels. Oxiracetam also normalized the ex vivo striatal SDHACU activity of decorticated rats 2 h after administration without any effect in sham-operated rats. Oxiracetam or choline chloride administered before oxotremorine (0.8 mg/kg, i.p.) or apomorphine (1 mg/kg, i.p.) reinstated the ACh-increasing effect of these agonists. It is suggested that choline chloride acts directly simply by being the precursor for ACh, whereas oxiracetam may act indirectly, possibly by increasing the availability of choline chloride for ACh synthesis. Furthermore, the frontally decorticated rat could constitute a useful model for studying means to restore the deficit in striatal cholinergic neurotransmission.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2299354     DOI: 10.1111/j.1471-4159.1990.tb01909.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  1 in total

1.  Oxiracetam antagonizes the disruptive effects of scopolamine on memory in the radial maze.

Authors:  M Magnani; O Pozzi; R Biagetti; S Banfi; L Dorigotti
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.